Heron Therapeutics Inc vs Intel Corp — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Intel Corp trades at $105.07 (market cap $487.82B). The key difference: Intel Corp is far larger — about 5333.7× Heron Therapeutics Inc's market cap, and Intel Corp pays a 2.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | INTC | |
|---|---|---|
Market Cap | $91.46M | $487.82B |
Sector | Health | Technology |
52-Week High | $1.96 | $140.94 |
52-Week Low | $0.39 | $19.31 |
Enterprise Value | $189.36M | $500.07B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Intel (INTC) trades at $97.87, up 2.97% on the day, with technical indicators showing a bullish overall signal despite mixed moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$267 million in 2025. Recent news highlights volatility in semiconductor stocks amid AI-driven market shifts, with Intel expanding its Google Cloud AI partnership to boost enterprise growth.
Intel's outlook is cautiously optimistic, supported by earnings beats and strategic AI initiatives, but risks include intense competition, margin pressures, and sector volatility. The consensus price target of $109.55 suggests potential upside, though investors must weigh financial recovery against technological challenges in a dynamic chip market.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →